FDA's Proposed Rule for Oversight of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy - Key Considerations & Open Questions | Goodwin

After an over decade-long discourse amongst interested stakeholders, on October 3, 2023, FDA unveiled its proposed rule and policy to increase oversight over LDTs. If...

Related Keywords

,Clinical Laboratory Improvement Amendments ,Public Health Surveillance ,Academic Medical Centers Amcs ,Veterans Health Administration ,Tests Subject ,Phaseout Policy ,Leukocyte Antigen ,Law Enforcement ,Public Health ,Remain Under Active ,Federal Food ,Cosmetic Act ,Blood Donor Screening ,Medical Device User Fee Amendments ,Unique Device Identification ,Investigational Device Exemption ,Small Business Determination ,Devices Program ,Safer Technologies Program ,Medical Centers ,Validation Programs ,New York State Department ,Health Clinical Laboratory Evaluation Program ,Veterans Health ,Q Submission Program ,Small Business Certification ,Consolidated Appropriations Act ,Sunshine Act ,